- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
JPMorgan Chase & Co. Sells Omnicell, Inc. $OMCL Shares
Institutional investor decreases stake in healthcare technology company
Published on Mar. 4, 2026
Got story updates? Submit your updates here. ›
JPMorgan Chase & Co. decreased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 94.2% during the 3rd quarter, according to the company's recent 13F filing with the Securities and Exchange Commission. The fund previously owned 515,352 shares of the company's stock, but sold 8,362,010 shares during the period.
Why it matters
Omnicell is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The significant decrease in JPMorgan Chase & Co.'s stake could signal a shift in investor sentiment or portfolio strategy regarding Omnicell's business and future prospects.
The details
According to the 13F filing, JPMorgan Chase & Co. now owns only 1.12% of Omnicell, down from a previous stake of over 95%. The filing indicates the institutional investor sold a large number of Omnicell shares during the 3rd quarter of the year. Other institutional investors, such as Assenagon Asset Management S.A. and Acadian Asset Management LLC, have also made changes to their Omnicell holdings recently.
- JPMorgan Chase & Co. decreased its Omnicell stake during the 3rd quarter of 2026.
The players
JPMorgan Chase & Co.
A major American multinational investment bank and financial services company.
Omnicell, Inc.
A healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies.
The takeaway
The significant decrease in JPMorgan Chase & Co.'s Omnicell stake could signal a shift in investor sentiment or portfolio strategy regarding the healthcare technology company. Investors will likely watch to see if other institutional investors follow suit or if Omnicell is able to attract new investors to offset the loss of this major shareholder.
